Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24988130 | 1.00 | CFTR (0.32) | CFTRGABRA5KDM4EALDH1A1HTT | |
| SCHEMBL24987619 | 1.00 | CFTR (0.32) | CFTRGABRA5KDM4EALDH1A1HTT | |
| SCHEMBL24985910 | 0.94 | CFTR (0.33) | CFTRGABRA5POLBKMT2A | |
| SCHEMBL24985908 | 0.94 | CFTR (0.33) | CFTRGABRA5POLBKMT2A | |
| SCHEMBL24984882 | 0.93 | PIK3CA (0.32) | CFTRGABRA5 | |
| SCHEMBL24984881 | 0.93 | PIK3CA (0.32) | CFTRGABRA5 | |
| SCHEMBL23905261 | 0.93 | PIK3CA (0.32) | CFTRGABRA5 | |
| SCHEMBL24986121 | 0.93 | GABRA5 (0.34) | CFTRGABRA5POLBKMT2A | |
| SCHEMBL24986117 | 0.93 | GABRA5 (0.34) | CFTRGABRA5POLBKMT2A | |
| SCHEMBL23905737 | 0.92 | CFTR (0.32) | CFTRGABRA5POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021198981-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-10-07 | — | — | WO | disclosed |